The Ithaca, New York-based firm has submitted its molecular diagnostic instrument along with a test to detect chlamydia, gonorrhea, and trichomonas.
FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.
A San Jose, California-based company appears to be the first in the US to routinely offer nanopore sequencing as part of a testing lab service.
The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
New resistance tests for Mycoplasma genitalium and gonorrhea could help stave off superbugs, but guidelines and economic factors may hinder adoption.
The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.
The firm said its platform provides sample-to-answer results for two of the most frequently tested sexually transmitted infections, enabling rapid testing and treatment.
The Australian molecular diagnostics firm will use the funds to accelerate commercial expansion in North America and global markets.
The latest NYS Department of Health approval expands the company's CT/NG testing to samples from multiple relevant body sites.
The company received support from a Johns Hopkins University center focused on point-of-care device development for sexually transmitted infections.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.